A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease

Trial Profile

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Sickle cell anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms GBT-HOPE; HOPE
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 09 Jan 2018 According to a Global Blood Therapeutics media release, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor for the treatment of sickle cell disease (SCD), based on data from this and other 3 studies.
    • 11 Dec 2017 According to a Global Blood Therapeutics media release, the company plans to announce top-line data from part A of the study in the first half of 2018.
    • 13 Nov 2017 According to a Global Blood Therapeutics media release, top-line data is expected in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top